ROTIGOTINE patches (Neupro®) for Parkinson`s
... All Wales criteria for Shared Care can be found at: http://www.awmsg.org/docs/awmsg/medman/Criteria%20for%20Shared%20Care.pdf GMC guidance on Shared Care (2013) states: Decisions about who should take responsibility for continuing care or treatment after initial diagnosis or assessment should be bas ...
... All Wales criteria for Shared Care can be found at: http://www.awmsg.org/docs/awmsg/medman/Criteria%20for%20Shared%20Care.pdf GMC guidance on Shared Care (2013) states: Decisions about who should take responsibility for continuing care or treatment after initial diagnosis or assessment should be bas ...
Section 61 Review of treatment form
... a) on the next and subsequent occasions that the authority for the patient’s detention is renewed under Section 20(3), 20A(4) or 21B(2); b) at any other time if so required by CQC, and c) in the case of patients subject to a restriction order, at the end of the first six months, if treatment began d ...
... a) on the next and subsequent occasions that the authority for the patient’s detention is renewed under Section 20(3), 20A(4) or 21B(2); b) at any other time if so required by CQC, and c) in the case of patients subject to a restriction order, at the end of the first six months, if treatment began d ...
document - Herts Valleys CCG
... 1. Patients who have not previously been treated with an Anti-VEGF injection (Anti-VEGF naïve patients) – aflibercept (preferred choice as requires fewer follow ups) and ranibizumab. 2. Patients on ranibizumab who have benefitted but require frequent injections - by local agreement, the use of aflib ...
... 1. Patients who have not previously been treated with an Anti-VEGF injection (Anti-VEGF naïve patients) – aflibercept (preferred choice as requires fewer follow ups) and ranibizumab. 2. Patients on ranibizumab who have benefitted but require frequent injections - by local agreement, the use of aflib ...
Azathioprine - Wolverhampton Formulary
... the GP on any further dose adjustments required. 5. Ask the GP whether he or she is willing to participate in shared care, and agree with the GP as to who will discuss the shared care arrangement with the patient. 6. Monitor FBC (including differential white cell count) and LFTs (including transamin ...
... the GP on any further dose adjustments required. 5. Ask the GP whether he or she is willing to participate in shared care, and agree with the GP as to who will discuss the shared care arrangement with the patient. 6. Monitor FBC (including differential white cell count) and LFTs (including transamin ...
Section 61 Review of treatment form
... a) on the next and subsequent occasions that the authority for the patient’s detention is renewed under Section 20(3), 20A(4) or 21B(2); b) at any other time if so required by CQC, and c) in the case of patients subject to a restriction order, at the end of the first six months, if treatment began d ...
... a) on the next and subsequent occasions that the authority for the patient’s detention is renewed under Section 20(3), 20A(4) or 21B(2); b) at any other time if so required by CQC, and c) in the case of patients subject to a restriction order, at the end of the first six months, if treatment began d ...
Ciclosporin - Wolverhampton Formulary
... be explained to the patient by the doctor initiating treatment. It is important that patients are consulted about treatment and are in agreement with it. Patients who have undergone renal transplant are under regular follow-up, which provides opportunities to discuss drug therapy. The doctor who pre ...
... be explained to the patient by the doctor initiating treatment. It is important that patients are consulted about treatment and are in agreement with it. Patients who have undergone renal transplant are under regular follow-up, which provides opportunities to discuss drug therapy. The doctor who pre ...
Lipid-modifying treatment
... • For primary prevention in people without type 2 diabetes, no target for total or LDL-cholesterol is recommended. Do not use higher intensity statinsa routinely. • For secondary prevention in people without type 2 diabetes, consider increasing to simvastatin 80mg if both the total cholesterol and t ...
... • For primary prevention in people without type 2 diabetes, no target for total or LDL-cholesterol is recommended. Do not use higher intensity statinsa routinely. • For secondary prevention in people without type 2 diabetes, consider increasing to simvastatin 80mg if both the total cholesterol and t ...
C: Applications of Clinical Decision Support Systems
... More specialized examples include two systems that provide reminders to perform blood pressure measurement and cervical cancer screening, respectively.14 The HealthQuiz program elicits background information and risk factors from patients, then compares their answers to detailed preventive care guid ...
... More specialized examples include two systems that provide reminders to perform blood pressure measurement and cervical cancer screening, respectively.14 The HealthQuiz program elicits background information and risk factors from patients, then compares their answers to detailed preventive care guid ...
Detailed Advice - Scottish Medicines Consortium
... • A number of issues were identified with the indirect comparisons carried out to demonstrate equivalent efficacy between erdosteine and the other two licensed mucolytics. Due to problems with the clinical data used in the economic evaluation, it is difficult to estimate what the incremental benefit ...
... • A number of issues were identified with the indirect comparisons carried out to demonstrate equivalent efficacy between erdosteine and the other two licensed mucolytics. Due to problems with the clinical data used in the economic evaluation, it is difficult to estimate what the incremental benefit ...
The IT suites will be closed for staff training purposes on the dates
... the need to motivate and educate the patient in order to enable them to make informed decisions should be considered. ...
... the need to motivate and educate the patient in order to enable them to make informed decisions should be considered. ...
Guideline for agitation in Alzheimer`s dementia - G-Care
... Medicines Information Services: Gloucester 0300 422 6108 (Mon to Fri, 9 – 5.30pm) Cheltenham 0300 422 3030 (Mon to Fri, 9 – 5.30pm) Written: … 2016 ...
... Medicines Information Services: Gloucester 0300 422 6108 (Mon to Fri, 9 – 5.30pm) Cheltenham 0300 422 3030 (Mon to Fri, 9 – 5.30pm) Written: … 2016 ...
1. circumstances when shared care is appropriate
... prescribe, we suggest you discuss this with your local Trust/specialist service, which will be willing to provide training and support. If you still lack the confidence to accept clinical responsibility, you still have the right to decline. Your CCG pharmacist will assist you in making decisions abo ...
... prescribe, we suggest you discuss this with your local Trust/specialist service, which will be willing to provide training and support. If you still lack the confidence to accept clinical responsibility, you still have the right to decline. Your CCG pharmacist will assist you in making decisions abo ...
No Slide Title
... difficult to make because of variations in the evidence base for individual drugs and in the length of treatment follow up. ...
... difficult to make because of variations in the evidence base for individual drugs and in the length of treatment follow up. ...
presentation
... package, now required as a benefit level floor under the Affordable Care Act (ACA), network adequacy standards will determine what care is covered and how easily it can be obtained. ...
... package, now required as a benefit level floor under the Affordable Care Act (ACA), network adequacy standards will determine what care is covered and how easily it can be obtained. ...
Protocol for the administration of Hydroxocobalamin
... performing basic life support and underpinning knowledge of consent issues. 3) The HCA will undergo a period of supervised practice and to be directly observed administering 5x intramuscular injections of hydroxocobalamin either by the general practitioner or the practice nurse (GP employee) providi ...
... performing basic life support and underpinning knowledge of consent issues. 3) The HCA will undergo a period of supervised practice and to be directly observed administering 5x intramuscular injections of hydroxocobalamin either by the general practitioner or the practice nurse (GP employee) providi ...
nhs dorset clinical commissioning group position
... 10. This document is for guidance only - all doctors have responsibility for their own prescriptions and have to bear in mind licensing issues as well as evidence base. 11. Patient groups for whom the new oral anti-coagulants are particularly suited: Those with significant, recognised, unwanted si ...
... 10. This document is for guidance only - all doctors have responsibility for their own prescriptions and have to bear in mind licensing issues as well as evidence base. 11. Patient groups for whom the new oral anti-coagulants are particularly suited: Those with significant, recognised, unwanted si ...
Midodrine
... system which include low blood pressure, neuro-cardiogenic syncope (fainting) and postural tachycardia syndrome. It is used only after other measures have been ineffective in controlling symptoms (e.g. high fluid intake, additional salt in some patients, counter manoeuvres, small ...
... system which include low blood pressure, neuro-cardiogenic syncope (fainting) and postural tachycardia syndrome. It is used only after other measures have been ineffective in controlling symptoms (e.g. high fluid intake, additional salt in some patients, counter manoeuvres, small ...
Acute kidney injury and sick day rules
... ‘Think Kidneys’ website: www.thinkkidneys.nhs.uk. On the basis of this, many localities have introduced, or are in the process of introducing, AKI pathways and sick day rules/guidance. The premise here is that interventions directed towards these high risk patients will improve their clinical outcom ...
... ‘Think Kidneys’ website: www.thinkkidneys.nhs.uk. On the basis of this, many localities have introduced, or are in the process of introducing, AKI pathways and sick day rules/guidance. The premise here is that interventions directed towards these high risk patients will improve their clinical outcom ...
A “Compare and Contrast” of International Guidelines - IPAC-RS
... § Subsequent market entry ICS products that are considered to be new drugs are subject to the requirements of Division 8, Part C of the Food and Drug Regulations. Abbreviated New Drug Submissions (ANDS) and Supplemental New Drug Submissions (SNDS) in support of these drug products are required to co ...
... § Subsequent market entry ICS products that are considered to be new drugs are subject to the requirements of Division 8, Part C of the Food and Drug Regulations. Abbreviated New Drug Submissions (ANDS) and Supplemental New Drug Submissions (SNDS) in support of these drug products are required to co ...
Buccal Midazolam
... seizures or status epilepticus can be shared between the specialist and the general practitioner (GP). GPs are invited to participate but if the GP is not confident to undertake these roles, they are under no obligation to do so. In such an event, the clinical responsibility for the patient in respe ...
... seizures or status epilepticus can be shared between the specialist and the general practitioner (GP). GPs are invited to participate but if the GP is not confident to undertake these roles, they are under no obligation to do so. In such an event, the clinical responsibility for the patient in respe ...
Using the PICO model to formulate a search question
... • Patient or patient group (gender, race, age) • Disease or condition • Stage of the illness • Care setting ...
... • Patient or patient group (gender, race, age) • Disease or condition • Stage of the illness • Care setting ...
Biologic Response Modifier Agents for Adults with
... The information in this Project in Brief is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policymakers make well-informed decisions and thereby improve the quality of health care services. The information in this Project in Brief shoul ...
... The information in this Project in Brief is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policymakers make well-informed decisions and thereby improve the quality of health care services. The information in this Project in Brief shoul ...
Mental Health in Primary Care
... Primary Care Mental Health • 281 million consultations in Primary Care ...
... Primary Care Mental Health • 281 million consultations in Primary Care ...
Anxiety - Catterick & Colburn Medical Group
... – Long treatment and doses at high end of dose range may be needed – Review efficacy and side effects within 2 weeks of starting treatment and at 4, 6 and 12 weeks – If improvement after 12 weeks, continue treatment with review at 8-12 week intervals – If no improvement after 12 weeks of SSRI consid ...
... – Long treatment and doses at high end of dose range may be needed – Review efficacy and side effects within 2 weeks of starting treatment and at 4, 6 and 12 weeks – If improvement after 12 weeks, continue treatment with review at 8-12 week intervals – If no improvement after 12 weeks of SSRI consid ...